Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer.

IF 3.1 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Cardiology Reports Pub Date : 2024-09-01 Epub Date: 2024-07-23 DOI:10.1007/s11886-024-02099-2

Amit Manhas, Dipti Tripathi, Dilip Thomas, Nazish Sayed

{"title":"Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer.","authors":"Amit Manhas, Dipti Tripathi, Dilip Thomas, Nazish Sayed","doi":"10.1007/s11886-024-02099-2","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review explores the cardiovascular toxicity associated with cancer therapies, emphasizing the significance of the growing field of cardio-oncology. It aims to elucidate the mechanisms of cardiotoxicity due to radiotherapy, chemotherapy, and targeted therapies, and to discuss the advancements in human induced pluripotent stem cell technology (hiPSC) for predictive disease modeling.Recent findings: Recent studies have identified several chemotherapeutic agents, including anthracyclines and kinase inhibitors, that significantly increase cardiovascular risks. Advances in hiPSC technology have enabled the differentiation of these cells into cardiovascular lineages, facilitating more accurate modeling of drug-induced cardiotoxicity. Moreover, integrating hiPSCs into clinical trials holds promise for personalized cardiotoxicity assessments, potentially enhancing patient-specific therapeutic strategies. Cardio-oncology bridges oncology and cardiology to mitigate the cardiovascular side-effects of cancer treatments. Despite advancements in predictive models using hiPSCs, challenges persist in accurately replicating adult heart tissue and ensuring reproducibility. Ongoing research is essential for developing personalized therapies that balance effective cancer treatment with minimal cardiovascular harm.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cardiology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11886-024-02099-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review explores the cardiovascular toxicity associated with cancer therapies, emphasizing the significance of the growing field of cardio-oncology. It aims to elucidate the mechanisms of cardiotoxicity due to radiotherapy, chemotherapy, and targeted therapies, and to discuss the advancements in human induced pluripotent stem cell technology (hiPSC) for predictive disease modeling.

Recent findings: Recent studies have identified several chemotherapeutic agents, including anthracyclines and kinase inhibitors, that significantly increase cardiovascular risks. Advances in hiPSC technology have enabled the differentiation of these cells into cardiovascular lineages, facilitating more accurate modeling of drug-induced cardiotoxicity. Moreover, integrating hiPSCs into clinical trials holds promise for personalized cardiotoxicity assessments, potentially enhancing patient-specific therapeutic strategies. Cardio-oncology bridges oncology and cardiology to mitigate the cardiovascular side-effects of cancer treatments. Despite advancements in predictive models using hiPSCs, challenges persist in accurately replicating adult heart tissue and ensuring reproducibility. Ongoing research is essential for developing personalized therapies that balance effective cancer treatment with minimal cardiovascular harm.

Abstract Image

查看原文本刊更多论文

癌症治疗中的心血管毒性：在抗癌的同时保护心脏。

综述的目的：这篇综述探讨了与癌症疗法相关的心血管毒性，强调了不断发展的心肿瘤学领域的重要性。它旨在阐明放疗、化疗和靶向治疗导致心脏毒性的机制，并讨论用于疾病预测建模的人类诱导多能干细胞技术（hiPSC）的进展：最近的研究发现，包括蒽环类和激酶抑制剂在内的几种化疗药物会显著增加心血管风险。hiPSC 技术的进步使这些细胞能够分化成心血管系，从而有助于更准确地模拟药物引起的心脏毒性。此外，将 hiPSC 纳入临床试验有望进行个性化心脏毒性评估，从而有可能加强针对患者的治疗策略。肿瘤心脏病学是肿瘤学和心脏病学的桥梁，可减轻癌症治疗对心血管的副作用。尽管利用 hiPSCs 建立预测模型取得了进展，但在准确复制成人心脏组织和确保可重复性方面仍存在挑战。要想开发出既能有效治疗癌症，又能将对心血管的伤害降到最低的个性化疗法，持续的研究是必不可少的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Cardiology Reports CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

6.20

自引率

2.70%

发文量

209

期刊介绍： The aim of this journal is to provide timely perspectives from experts on current advances in cardiovascular medicine. We also seek to provide reviews that highlight the most important recently published papers selected from the wealth of available cardiovascular literature. We accomplish this aim by appointing key authorities in major subject areas across the discipline. Section editors select topics to be reviewed by leading experts who emphasize recent developments and highlight important papers published over the past year. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. We also provide commentaries from well-known figures in the field.